Cargando…

Editorial: Immunotherapy for NSCLC with oncogenic driver variants

Detalles Bibliográficos
Autores principales:	Du, Yijia, Chu, Qian, Lou, Yanyan, He, Yong, Hu, Hongbo, Hu, Qipeng, Huang, Meijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775290/ https://www.ncbi.nlm.nih.gov/pubmed/36568249 http://dx.doi.org/10.3389/fonc.2022.1095947

Ejemplares similares

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
por: Malapelle, Umberto, et al.
Publicado: (2023)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
por: Zhang, Zhimin, et al.
Publicado: (2021)

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors
por: Zhang, Runjiao, et al.
Publicado: (2021)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Editorial: Personalized immunotherapy for cancer
por: Pasetto, Anna, et al.
Publicado: (2023)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
por: Su, Chunxia, et al.
Publicado: (2022)

Induction of Ferroptosis by Ophiopogonin-B Through Regulating the Gene Signature AURKA in NSCLC
por: Li, Liqiu, et al.
Publicado: (2022)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI
por: Zhang, He, et al.
Publicado: (2022)

Editorial: Targeting Phosphorylation and Glycosylation of Membrane-Bound Oncogenic Drivers, Receptors and Adhesion Molecules to Control Constitutive Proliferation of Human Carcinoma Cells
por: Hussain, Muhammad R. M., et al.
Publicado: (2018)

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study
por: Wu, Minghao, et al.
Publicado: (2022)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers
por: Qian, Yawei, et al.
Publicado: (2023)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Editorial: The role of immunotherapy in melanomas
por: Fateeva, Anna, et al.
Publicado: (2023)

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
por: Konstantinidou, Georgia, et al.
Publicado: (2020)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy
por: Liu, Bin, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ipsijvif5i7ll83t731j6kd8ld